[go: up one dir, main page]

PE20020665A1 - ACIDO CICLOALQUIL FENIL ALCANOICO COMO ANTAGONISTA DE INTEGRINAS OVß3 - Google Patents

ACIDO CICLOALQUIL FENIL ALCANOICO COMO ANTAGONISTA DE INTEGRINAS OVß3

Info

Publication number
PE20020665A1
PE20020665A1 PE2001000575A PE2001000575A PE20020665A1 PE 20020665 A1 PE20020665 A1 PE 20020665A1 PE 2001000575 A PE2001000575 A PE 2001000575A PE 2001000575 A PE2001000575 A PE 2001000575A PE 20020665 A1 PE20020665 A1 PE 20020665A1
Authority
PE
Peru
Prior art keywords
alkyl
ring
cycloalkyl
ovß3
phenyl
Prior art date
Application number
PE2001000575A
Other languages
English (en)
Inventor
Michael Clare
Alan F Gasiecki
Ish Kumar Khanna
Thomas Rogers
Mark Russell
Barbara B Chen
Hwang-Fun Lu
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of PE20020665A1 publication Critical patent/PE20020665A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A COMPUESTOS ACIDO CICLOALQUIL FENIL ALCANOICO DE FORMULA I DONDE EL ANILLO A ES UN ANILLO MONOCICLICO DE 4-8 MIEMBROS, ANILLO BICICLICO DE 7-12 MIEMBROS; A1 ES UN ANILLO MONOCICLICO DE 5-9 MIEMBROS, HETEROCICLO POLICICLICO DE 7-14 MIEMBROS, NR5-C(=Y1)-NR8R7, NR5C(Y2)(=NR7); CUANDO Z1 ES CO, SO2, EL ENLACE A1-Z2 INCLUYE PIRIDINA, IMIDAZOL, TIAZOL, OXAZOL, BENZIMIDAZOL, IMIDAZOPIRIDINA; Y1 ES NR2, O, S; R2 ES H, ALQUILO, ARILO, OH, ALCOXI; R7 Y R8 SON H, ALQUILO, ARALQUILO, AMINO, ALQUILAMINO; NR7 Y R8 FORMAN UN ANILLO MONOCICLICO, BICICLICO; R5, Rm, Rp, Rk, Rf SON H, ALQUILO; A ES NR5C(Y)=NR'; Y2 ES ALQUILO, CICLOALQUILO, BICICLOALQUILO, ENTRE OROS; Z1 ES CH2, O, NH, NRk, ENTRE OTROS; Z2 ES UN ENLAZANTE C2-C5; Z1-Z2 CONTIENE ADEMAS CARBOXAMIDA, SULFONA, ENLAZADO AL ANILLO A EN POSICION PARA O META EN RELACION A X1; n ES 0-1; Rc ES H, ALQUILO, HALOGENO, OH, ENTRE OTROS; X1 ES O, CO, SO2, NRm, (CHRp)q; Rp ES H, ALQUILO, ALCOXI, OH; q ES 0-1; X2 ES CHRe, CO, SO2, NRf, S. X o Y ES CRg, N; Rg ES H, ALQUILO, HALOALQUILO, FLUORO, ENTRE OTROS, X-X2-Y CONTIENE ACILO, ALQUILO, AMINO, ENTRE OTROS; Rb ES X3-Rh; X3 ES O, S, NRj; Rj Y Rh SON H, ALQUILO, ACILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS ACIDO 2-[4-[3-(2-PIRIDINILAMINO)PROPOXI]FENIL]CICLOPROPANO-ACETICO, ENTRE OTROS. LOS COMPUESTOS SON ANTAGONISTAS DE INTEGRINAS OVß3 Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE METASTASIS TUMORAL, CRECIMIENTO TUMORAL, OSTEOPOROSIS, ENFERMEDAD DE PAGET, RETINOPATIA, DEGENERACION MACULAR
PE2001000575A 2000-06-15 2001-06-15 ACIDO CICLOALQUIL FENIL ALCANOICO COMO ANTAGONISTA DE INTEGRINAS OVß3 PE20020665A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21178100P 2000-06-15 2000-06-15

Publications (1)

Publication Number Publication Date
PE20020665A1 true PE20020665A1 (es) 2002-08-14

Family

ID=22788343

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000575A PE20020665A1 (es) 2000-06-15 2001-06-15 ACIDO CICLOALQUIL FENIL ALCANOICO COMO ANTAGONISTA DE INTEGRINAS OVß3

Country Status (8)

Country Link
US (2) US6900232B2 (es)
EP (1) EP1289960A2 (es)
JP (1) JP2004525069A (es)
AR (1) AR030701A1 (es)
AU (1) AU2001269821A1 (es)
PE (1) PE20020665A1 (es)
UY (1) UY26780A1 (es)
WO (1) WO2001096307A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176322B2 (en) 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
US6908935B2 (en) 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US7842693B2 (en) * 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
KR101255356B1 (ko) * 2002-06-12 2013-04-17 케모센트릭스, 인크. 염증 및 면역 질병의 치료를 위한 ｃｃｒ１ 길항물질로서사용하기 위한 1-아릴-4-치환된 피페라진 유도체
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
US20040259669A1 (en) * 2003-06-20 2004-12-23 Seaway Plastics Ltd. Volleyball net pretensioned with rigid side strips
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
US7435831B2 (en) * 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
WO2005084667A1 (en) * 2004-03-03 2005-09-15 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
EP1734996B1 (en) 2004-04-02 2013-05-22 The Regents of The University of California Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
CN103274961B (zh) 2004-12-28 2016-05-18 阿西纳斯公司 治疗细胞增殖紊乱的化合物和方法
CA2598423C (en) 2005-02-18 2014-05-27 Astrazeneca Ab Antibacterial piperidine derivatives
CN101595084B (zh) 2006-06-29 2013-01-02 金克斯医药品有限公司 用于调整激酶级联的二芳基组合物和方法
US7935697B2 (en) 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
BRPI0818658A2 (pt) 2007-10-09 2015-04-14 Merck Patent Ges Mit Beschränkter Haftung Derivados de piridina úteis como ativadores de glicoquinase
JP5637855B2 (ja) * 2007-11-08 2014-12-10 ザ ジェネラル ホスピタル コーポレイション 蛋白尿症の治療のための方法及び組成物
CN102481347A (zh) 2009-07-24 2012-05-30 加州大学董事会 治疗和预防整合素αvβ5相关疾病的方法及组合物
CN102905700A (zh) 2010-04-16 2013-01-30 金克斯医药品有限公司 用于预防和治疗癌症的组合物以及方法
CN109999040A (zh) 2012-08-30 2019-07-12 阿西纳斯公司 蛋白质酪氨酸激酶调节剂
RS64535B1 (sr) 2013-09-24 2023-09-29 Fujifilm Corp Farmaceutska kompozicija jedinjenja koje sadrži azot ili njegovu so, ili njihov kompleks sa metalom
CN113121450A (zh) 2014-08-29 2021-07-16 Tes制药有限责任公司 α-氨基-β-羧基粘康酸半醛脱羧酶抑制剂
CN116041169B (zh) * 2022-07-29 2025-10-24 北京先通国际医药科技股份有限公司 一种合成修饰脂肪酸型pet试剂前体关键中间体的工艺路线及其用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654306A (en) * 1970-01-26 1972-04-04 Robins Co Inc A H 5-azaspiro(2.4)heptane-4 6-diones
IL99537A (en) 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
GB9202792D0 (en) 1992-02-11 1992-03-25 British Bio Technology Compounds
WO1993021166A1 (en) 1992-04-10 1993-10-28 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of type ii-diabetes
GB9311282D0 (en) 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd New compositions of matter
GB9315148D0 (en) 1993-07-22 1993-09-08 Smithkline Beecham Plc Novel compounds
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
DE4408082A1 (de) 1994-03-10 1995-09-14 Hoechst Ag Substituierte Propan-Derivate, Verfahren zu ihrer Herstellung und die Anwendung der Verbindungen zur Behandlung von Krankheiten
ES2186720T3 (es) 1994-05-27 2003-05-16 Merck & Co Inc Composiciones para inhibir la reabsorcion osea mediada por osteoclastos.
US5710171A (en) * 1995-05-24 1998-01-20 Merck & Co., Inc. Bisphenyl inhibitors of farnesyl-protein transferase
CA2176854A1 (en) * 1995-06-07 1996-12-08 Daniel J. Keavy N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics
GB9511694D0 (en) 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
DE19536891A1 (de) 1995-10-04 1997-04-10 Basf Ag Neue Aminosäurederivate, ihre Herstellung und Verwendung
IT1276153B1 (it) 1995-11-17 1997-10-27 Roberto Pellicciari Derivati di glicina ad attivita' antagonista dei recettori metabotropi del glutammato
EP0889877B1 (en) 1996-03-29 2001-08-29 G.D. Searle & Co. META-SUBSTITUTED PHENYLENE DERIVATIVES AND THEIR USE AS ALPHAvBETA3 INTEGRIN ANTAGONISTS OR INHIBITORS
JP2000507575A (ja) * 1996-03-29 2000-06-20 ジー．ディー．サール アンド カンパニー シクロプロピルアルカノイック酸誘導体
JP2000510098A (ja) * 1996-03-29 2000-08-08 ジー．ディー．サール アンド カンパニー 桂皮酸誘導体
US6121288A (en) 1996-11-08 2000-09-19 Nippon Chemiphar Co., Ltd. Visceral fat lowering agent
JP2001509176A (ja) 1997-01-17 2001-07-10 メルク エンド カンパニー インコーポレーテッド インテグリンアンタゴニスト
JPH10287634A (ja) 1997-04-11 1998-10-27 Otsuka Pharmaceut Co Ltd ベンゼン誘導体
CO5080762A1 (es) 1998-03-10 2001-09-25 Smithkline Beechman Corp Antagonistas de receptor de vitronectina
UA71586C2 (en) * 1998-12-04 2004-12-15 Smithkline Beecham Corp A vitronectin receptor antagonist
IL143901A0 (en) 1998-12-23 2002-04-21 Searle & Co Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
DK1177187T3 (da) 1999-04-28 2007-10-15 Sanofi Aventis Deutschland Diarylsyrederivater som PPAR-receptorligander
DE60015539T2 (de) * 1999-05-05 2005-11-24 Aventis Pharma Ltd., West Malling Substituierte pyrrolidine als inhibitoren der zelladhäsion
DE19939980A1 (de) 1999-08-24 2001-03-01 Merck Patent Gmbh Inhibitoren des Integrins alphavbeta¶3¶
DE19939981A1 (de) 1999-08-24 2001-03-01 Merck Patent Gmbh Neue Inhibitoren des Integrins alphavß3

Also Published As

Publication number Publication date
US6900232B2 (en) 2005-05-31
UY26780A1 (es) 2002-01-31
AU2001269821A1 (en) 2001-12-24
JP2004525069A (ja) 2004-08-19
EP1289960A2 (en) 2003-03-12
US20040259869A1 (en) 2004-12-23
US6949578B2 (en) 2005-09-27
AR030701A1 (es) 2003-09-03
WO2001096307A2 (en) 2001-12-20
US20020077321A1 (en) 2002-06-20
WO2001096307A3 (en) 2002-08-15

Similar Documents

Publication Publication Date Title
PE20020665A1 (es) ACIDO CICLOALQUIL FENIL ALCANOICO COMO ANTAGONISTA DE INTEGRINAS OVß3
PE20010741A1 (es) Derivados de piperazina como antagonistas de taquicininas
JP2007505877A5 (es)
PE20060374A1 (es) Inhibidores de cinasa heterociclicos fusionados
EA200400830A1 (ru) ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ, ОТНОСЯЩИЕСЯ К A2b-СЕЛЕКТИВНЫМ АНТАГОНИСТАМ, ИХ СИНТЕЗ И ПРИМЕНЕНИЕ
PE20050132A1 (es) Piperazinas heterociclicas sustituidas
PE20020917A1 (es) Derivados de imidazol como bloqueadores del receptor n-metil-d-aspartato
RU2010131833A (ru) Способы получения производных хиназолинона
PE58399A1 (es) Atropisomeros de 3-aril-4(3h)-quinazolinonas
DE60228406D1 (de) PYRAZOLOÄ3,4-dÜPYRIMIDINDERIVATE UND IHRE VERWENDUNG ALS ANTAGONISTEN DES PURINERGEN REZEPTORS
PE20051046A1 (es) Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina
PE20120814A1 (es) Compuestos y composiciones como inhibidores de la proteina cinasa
PE20010219A1 (es) AGONISTAS ß-ADRENORRECEPTORES
JP2005508966A5 (es)
PE20020298A1 (es) Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona como antagonistas de receptores de neuroquinina nk-1
CA2078810A1 (en) Leukotriene biosynthesis inhibitors
PE20060693A1 (es) Nuevos derivados de trifluorometansulfonanilida oxamida eter
JP2005509622A5 (es)
PE20020483A1 (es) Peptidos ciclicos selectivos como agonistas de los receptores de melanocortina 4
PE20010753A1 (es) DERIVADOS DE PURINA COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2a
JPH04330073A (ja) アンギオテンシンｉｉ拮抗薬としての置換ピリドピリミジノン類及び関連複素環類
CA2624602A1 (en) Process for preparing 6-substituted-7-azaindoles
PE20070004A1 (es) Imidazoquinolinas como inhibidores de quinasa de lipido
PE20010854A1 (es) USO DE DERIVADOS DE PIRIMIDINA 4 SUSTITUIDOS COMO ANTAGONISTAS DE LOS RECEPTORES DE GLUTAMATO mGluR1
PE20021158A1 (es) Derivados de sulfonamida como antagonistas del receptor de bradiquinina

Legal Events

Date Code Title Description
FC Refusal